Avita Medical Inc.
AVH.ASXHealth Care
Regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration.
Market Data
$1.180
+0.0%$175.4M
-100000.0x
$-0.029
0.00%
-0.2%
Latest Earnings
Financial Results for Quarter Ending 31 March 2026
15 May 2026
AVITA Medical reported Q1 2026 revenue of $19.3M (up 4.0% YoY), with a net loss of $10.6M compared to $13.9M in Q1 2025, showing significant improvement in operational efficiency and cash management. The company refinanced its debt facility and reduced operating expenses by 11%, though it remains unprofitable and carries substantial debt obligations. Despite losses, the company is advancing its RECELL GO platform and managing cash burn more effectively with continued product portfolio expansion. Key points: Revenue growth of 4.0% YoY to $19.3M despite challenging market conditions, with stable gross margins of 81.7%; Net loss improved 23.4% YoY to $10.6M from $13.9M, and operating loss improved 25.5% to $8.8M from $11.8M, driven by 11% reduction in operating expenses; Successfully refinanced debt facility with $49.1M in proceeds, improving financial flexibility and extending debt maturity
Recent Announcements
AVITA Medical Q1 2026 Earnings Presentation
AVITA Medical reported Q1 2026 net revenue of $19.3 million (4.3% growth year-over-year) and reaffirmed full-year 2026 guidance of $80-85 million, supported by secured BARDA contract, Cohealyx clinical data showing ~20-day faster grafting times, and RECELL GO clearance in Australia and New Zealand.
Financial Results for Quarter Ending 31 March 2026
AVITA Medical reported Q1 2026 revenue of $19.3M (up 4.0% YoY), with a net loss of $10.6M compared to $13.9M in Q1 2025, showing significant improvement in operational efficiency and cash management. The company refinanced its debt facility and reduced operating expenses by 11%, though it remains unprofitable and carries substantial debt obligations. Despite losses, the company is advancing its RECELL GO platform and managing cash burn more effectively with continued product portfolio expansion. Key points: Revenue growth of 4.0% YoY to $19.3M despite challenging market conditions, with stable gross margins of 81.7%; Net loss improved 23.4% YoY to $10.6M from $13.9M, and operating loss improved 25.5% to $8.8M from $11.8M, driven by 11% reduction in operating expenses; Successfully refinanced debt facility with $49.1M in proceeds, improving financial flexibility and extending debt maturity
AVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical reported Q1 2026 revenue of $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx contributions and normalized RECELL utilization following reimbursement improvements. Net loss improved to $10.6M ($0.35 per share) from $13.9M ($0.53 per share) YoY, with operating expenses down 11% YoY reflecting cost discipline. The company reaffirmed full-year 2026 guidance of $80-85M revenue (12-19% growth) and expects significant improvement in cash burn in Q2 as timing dynamics reverse. Key points: Revenue growth of 4% YoY and 10% sequentially to $19.3M, driven by Cohealyx adoption and normalized RECELL utilization after reimbursement improvements; Net loss improved 23.5% to $10.6M ($0.35/share) from $13.9M ($0.53/share) YoY, demonstrating improving unit economics despite lower gross margin from product mix; Operating expenses decreased 11% YoY to $24.5M, reflecting sustained cost discipline and sales force optimization from 2025 restructuring
AVITA to Announce First Quarter 2026 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced it will report first quarter 2026 financial results on May 14, 2026 after U.S. market close, with a conference call and webcast scheduled for May 14 at 1:30 p.m. Pacific Time to discuss results and business highlights.
AVITA Q4 and FY25 Earnings Presentation
AVITA Medical reported FY2025 revenue of $71.6M (+11% growth) with strong 82.1% gross margins, while reducing net losses from $61.8M to $48.6M through disciplined cost management. The company has secured improved debt terms with a $60M facility and provided 2026 revenue guidance of $80-85M (12-19% growth). Key points: Strong revenue growth of 11% to $71.6M with consistent 82%+ gross margins; Significant improvement in net losses, reduced from $61.8M to $48.6M through cost discipline; Secured improved $60M debt facility with better terms (5-year maturity, interest-only payments)
AVITA Reports Q4 and Full Year 2025 Financial Results
AVITA Medical reported Q4 2025 revenue of $17.6M (down 4% vs Q4 2024) and full-year revenue of $71.6M (up 11% vs 2024), with ongoing reimbursement headwinds weighing on Q4 performance. The company improved cash efficiency with net cash use declining to $5.1M in Q4 and reduced operating expenses by 5% year-over-year, while securing $60M in new credit facilities in January 2026. Management provided 2026 revenue guidance of $80-85M (12-19% growth) as reimbursement issues are largely resolved. Key points: Full-year 2025 revenue grew 11% to $71.6M, within revised guidance range; Net cash use improved for third consecutive quarter to $5.1M in Q4 vs $6.2M in Q3; Operating expenses reduced 5% year-over-year to $24.7M in Q4, reflecting lower cost base
Appendix 4E and Annual Report (Form 10-K)
AVITA Medical reported 11% revenue growth to $71.6M for FY2025, driven by deeper market penetration and new product launches. Despite the revenue growth, the company posted a net loss of $48.6M (down 21% from prior year) and faces substantial doubt about its ability to continue as a going concern over the next 12 months due to liquidity concerns. Key points: Revenue increased 11% to $71.6 million driven by deeper customer penetration and new accounts; Operating expenses decreased $10.4 million or 9% to $101.4 million through cost management; Net loss improved 21% to $48.6 million from $61.8 million in prior year
Get real-time alerts for AVH
Receive AI-powered earnings summaries and instant notifications when Avita Medical Inc. releases results.
Register Free